Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 7868 792050
ISSN: 2329-8790
+44 7868 792050
Research Article
Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era
Author(s): Renata de Oliveira Costa, Abrahão Hallack Neto, Sheila Siqueira, Luis Alberto de Padua Covas Lage, Henrique Moura de Paula and Juliana PereiraRenata de Oliveira Costa, Abrahão Hallack Neto, Sheila Siqueira, Luis Alberto de Padua Covas Lage, Henrique Moura de Paula and Juliana Pereira
Introduction: To evaluate a new enhanced IPI proposal by the National Comprehensive Cancer Network (NCCNIPI) in DLBCL patients, we compared the IPI, R-IPI, and NCCN-IPI in DLBCL patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP).
Methods: From June 2008 to January 2012, we retrospectively evaluated 146 DLBCL patients treated with RCHOP- 21 referred for cancer treatment in a single institution in Brazil. Patients' clinical data were assessed to calculate the IPI, R-IPI, and NCCN-IPI.
Results: Patients' median age was 58.9 years (range 16-86); 85 (57.8%) were female. According to IPI, risk categories were low (n=41, 28.1%), low-intermediate (n=43, 29.5%), high-intermediate (n=37, 25.3%), and high (n=25, 17.1%). Using R-IPI, risk categories were very go.. View More»
DOI:
10.4172/2329-8790.1000248